NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs

NEXT STORY
Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results
PREV STORY
What Does it Mean to Be The Imaginative Agency in Health and Wellness?
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OxOnc Announces that Co-development Partner Has Received Approval in Japan and Taiwan for Crizotinib (Xalkori®) as a First-line Treatment for Patients with ROS1-Positive Non-Small Cell Lung Cancer

CAYMAN ISLANDS, June 02, 2017 (GLOBE NEWSWIRE) -- OxOnc Development LP (OxOnc) today announced ...

author_avatar
NASDAQ Market News

Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

author_avatar
NASDAQ Market News

Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics

author_avatar
NASDAQ Market News